Epidemiologic research to improve lymphoma outcomes
Our lab uses epidemiologic methods to understand the causes and improve outcomes of cancers of the blood and lymph nodes, including Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Overview
Under the direction of principal investigator James R. Cerhan, M.D., Ph.D., the Lymphoma Epidemiology Laboratory at Mayo Clinic uses epidemiologic methods to advance scientific understanding about causes, treatments and outcomes for cancers of the lymphatic system and bone marrow.
In particular, our lab focuses its research efforts on these cancers:
Although researchers have made progress in understanding these cancers, there is still much to learn about their causes, prevention, diagnosis, treatment and survivorship.
Research goals
One of our lab's major research goals is to learn more about the environmental, lifestyle, genetic and biologic factors that might contribute to causing Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. We use large epidemiologic studies (both cohort and case-control studies) combined with state-of-the-art technology to investigate these factors and understand their underlying mechanisms, with the goal of improved cancer prevention and early detection.
Our other major goal is to identify lifestyle, genetic, tumor and treatment factors that are associated with better cancer outcomes and survivorship for people with lymphoma.
Our lab also maintains an epidemiology data and biospecimens resource that researchers at Mayo Clinic and around the world use to investigate these factors.
Studies that we use to address these issues include:
- Case-control studies that analyze possible causes of Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. These studies include information about medical history, pesticides and other farming exposures, diet and early-life factors, and genetic susceptibility.
- The Lymphoma Epidemiology of Outcomes (LEO) cohort study. This study enrolled people newly diagnosed with lymphoma and follows them over both the short and long term with the goal of improving survival, overall health and quality of life.
Funding
Our lab has received extensive funding from the U.S. National Institutes of Health (NIH) and other sources. Funding helps support our research on the epidemiology of lymphoma risk and outcomes.
Review Dr. Cerhan's grant information.